ALK and non-small cell lung carcinoma: To find effective targets that promote cell survival against ALK inhibition in ALK + NSCLC cells, we generated DTP cells that survive targeted therapy through reversible and non-mutational mechanisms from ALK + NCI-H2228 cells following exposure to alectinib11.